Shinichi Oka
Experienced in Intestinal Pseudo-Obstruction

Shinichi Oka

Tokyo, JP 
Experienced in Intestinal Pseudo-Obstruction
Tokyo, JP 
OverviewLocationsClinical Research

Overview

Shinichi Oka practices in Tokyo, Japan. Mr. Oka is rated as an Experienced expert by MediFind in the treatment of Intestinal Pseudo-Obstruction. His top areas of expertise are HIV/AIDS, Pneumocystis Jiroveci Pneumonia, Amebiasis, Endoscopy, and Gastrectomy.

His clinical research consists of co-authoring 391 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Intestinal Pseudo-Obstruction.

Gender
Male

Locations

Tokyo, Japan
Other Locations
Sapporo, 0608556, Japan
Shinjuku, Japan
Chiba, Japan
Kumamoto, Japan
Hongo, 1138431, Japan
Urayasu, 2790021, Japan
Japan
Ichikawa, Japan
Chuo, Japan
Toyama, 1628655, Japan
Hidaka, 3501298, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed
A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed
Enrollment Status: Completed
Publish Date: June 04, 2024
Intervention Type: Drug
Study Drugs: Cabotegravir, Rilpivirine, BIKTARVY
Study Phase: Phase 3

390 Total Publications

Month 12 outcomes of switching to long-acting cabotegravir + rilpivirine with an oral lead-in versus continuing bictegravir/ emtricitabine/tenofovir alafenamide in the Phase 3b randomized SOLAR study.
Month 12 outcomes of switching to long-acting cabotegravir + rilpivirine with an oral lead-in versus continuing bictegravir/ emtricitabine/tenofovir alafenamide in the Phase 3b randomized SOLAR study.
Journal: Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
Published: September 30, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Oka's expertise for a condition
ConditionClose
View All 12 Advanced Conditions
View All 56 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile